Clearside Biomedical appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical, Inc.

Mr. Gibney appointed as a Class III director effective April 15, 2024; term runs through 2025 annual meeting.
He brings over 25 years biotech experience including Iveric Bio, Achillion, and Leerink Partners.
Received an option to purchase 45,000 shares of CLSD common stock vesting over 36 months.
Entitled to $40,000 annual retainer plus additional annual option grants for continuous service.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anthony S. Gibney

Director

CLSDQ · Clearside Biomedical, Inc.

Effective: 2024-04-15
Filed: April 16, 2024, 7:59 PM ET

On April 15, 2024, the Board of Directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Anthony S. Gibney to serve as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Anthony S. Gibney was appointed as Director at Clearside Biomedical, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 15, 2024, the Board of Directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Anthony S. Gibney to serve as a director of the Company.

View on SEC.gov

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-044594

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.